Literature DB >> 8880025

Mode of death in chronic heart failure. A request and proposition for more accurate classification.

R Narang1, J G Cleland, L Erhardt, S G Ball, A J Coats, A J Cowley, H J Dargie, A S Hall, J R Hampton, P A Poole-Wilson.   

Abstract

The proportion of patients reported to die suddenly or from progressive circulatory failure is not consistent among studies of heart failure. Lack of an adequate or consistent classification of how patients die contributes to the current confusion over the mode of death in heart failure. Defining how patients with heart failure die could be important in developing strategies to reduce the continuing high mortality associated with this condition. We identified 27 studies that reported 50 or more deaths among patients with heart failure to ascertain how death was classified. Definitions of sudden death appeared heterogeneous and the majority of studies failed to publish or make reference to how circulatory failure was defined. A framework for the classification of the mode of death has been developed in which clear separation of the activity and place at the time of death, cause of death, mode of death, and events prior to death is made (ACME: Activity, Cause, Mode and Event). This mode of classifying death has been successfully piloted in two mortality studies; AIRE and NETWORK. Classifying mortality in this way will help identify pathways leading to death and hence suggest therapies and strategies to reduce mortality in patients with heart failure, a group of patients whose prognosis remains poor.

Entities:  

Mesh:

Year:  1996        PMID: 8880025     DOI: 10.1093/oxfordjournals.eurheartj.a015074

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  21 in total

1.  Mode of death in heart failure: findings from the ATLAS trial.

Authors:  P A Poole-Wilson; B F Uretsky; K Thygesen; J G F Cleland; B M Massie; L Rydén
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

2.  The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction.

Authors:  Hasan Ali Barman; Eser Durmaz; Adem Atici; Serdar Kahyaoglu; Ramazan Asoglu; Irfan Sahin; Baris Ikitimur
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-06-02       Impact factor: 1.468

Review 3.  Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia.

Authors:  E C Palma
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

4.  Sudden unexpected death in heart failure may be preceded by short term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study.

Authors:  A M A Shehab; R J MacFadyen; M McLaren; R Tavendale; J J F Belch; A D Struthers
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

Review 5.  Genomics, heart failure and sudden cardiac death.

Authors:  Dawood Darbar
Journal:  Heart Fail Rev       Date:  2008-04-24       Impact factor: 4.214

6.  High-Dose Torasemide is Equivalent to High-Dose Furosemide with Hypertonic Saline in the Treatment of Refractory Congestive Heart Failure.

Authors:  Salvatore Paterna; Sergio Fasullo; Pietro Di Pasquale
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 7.  Devices for the management of ventricular arrhythmias in cardiac failure.

Authors:  Michael Cooklin
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

8.  Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly?

Authors:  Ricardo Mourilhe Rocha; Guilherme Vienna Silva; Emerson C Perin; André Regazzi Gerk; Ellas Pimentel Gouvea; Valéria Martin Soares Santos; Francisco Manes Albanesi Filho; Denilson Campos de Albuquerque
Journal:  Tex Heart Inst J       Date:  2003

9.  The inhibition in tumor necrosis factor-alpha-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-kappaB and reactive oxygen species.

Authors:  Pen-Yuan Lin; Hsi-Che Shen; Chien-Jen Chen; Shu-En Wu; Hsien-Li Kao; Jen-Hung Huang; Danny Ling Wang; Shih-Chung Chen
Journal:  J Thromb Thrombolysis       Date:  2009-03-31       Impact factor: 2.300

Review 10.  Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention.

Authors:  Ferruccio De Lorenzo; Neelam Saba; Vijay V Kakkar
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.